Evidence map›Paper›PMID 29291209›Full record

ArticleVirusdisease2017

Recent advances in vaccine development against Ebola threat as bioweapon.

Prachi Gera, Ankit Gupta, Priyanka Verma, Joginder Singh, Jeena Gupta

Abstract readEditorial
In one paragraph

Article in Virusdisease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Prachi GeraDepartment of Forensic Science, UIPS, Chandigarh University, Chandigarh, Punjab India.
Ankit GuptaDepartment of Forensic Science, UIPS, Chandigarh University, Chandigarh, Punjab India.
Priyanka VermaDepartment of Forensic Science, UIPS, Chandigarh University, Chandigarh, Punjab India.
Joginder SinghDepartment of Bioengineering and Biosciences, Lovely Professional University (LPU), Jalandhar - Delhi G.T. Road (NH-1), Phagwara, Punjab 144411 India.
Jeena GuptaDepartment of Bioengineering and Biosciences, Lovely Professional University (LPU), Jalandhar - Delhi G.T. Road (NH-1), Phagwara, Punjab 144411 India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the increasing rate of Ebola virus appearance, with multiple natural outbreaks of Ebola hemorrhagic fever, it is worthy of consideration as bioweapon by anti-national groups. Further, with the non-availability of the vaccines against Ebola virus, concerns about the public health emerge. In this regard, this review summarizes the structure, genetics and potential of Ebola virus to be used as a bioweapon. We highlight the recent advances in the treatment strategies and vaccine development against Ebola virus. The understanding of these aspects might lead to effective treatment practices which can be applied during the future outbreaks of Ebola.

Indexed as

BioweaponEbola hemorrhagic feverEbola outbreakEbola vaccineEbola virus

Identifiers

PMID29291209
PMCPMC5685003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.